Bridging the Gap Between Private and Public Markets.

We invest across the global healthcare industry and investments are made across the capital structure in one of two complementary strategies: private equity and public equity.

Private Equity
Our initial platform established in 2013.

Public Equity
A long-biased strategy launched in 2018.

We seek to deliver superior returns through our understanding of value across private and public markets.

Global Knowledge. Local Talent. Cross Market Expertise.

We aim to reap synergies across our private equity and public equity platforms, by attempting to leverage the strength of our global franchise to source and secure opportunities for our investors in high-impact life science innovation.

Frank Yu
Founder, Co-Chief Executive Officer, Co-Chief Investment Officer

Frank Yu founded Ally Bridge Group in 2013 and is Co-Chief Executive Officer and Co-Chief Investment Officer. In this capacity, Frank is responsible for setting firmwide strategic initiatives and leading investment objectives across high-impact life science transactions in private and public markets globally. Before founding Ally Bridge Group’s predecessor company in 2009, Themes Investment Partners, Frank was a Managing Director and Head of China Investments at Sculptor Capital Management (formerly Och-Ziff Capital Management). Before that, Frank spent nearly a decade at Goldman Sachs in Hong Kong, initially in Credit Risk Management and then in the Investment Banking Division as a Managing Director. Frank began his career as a Research Associate at Moody’s in New York before joining Credit Suisse as a Risk Officer in London and then Hong Kong. Frank holds a BA in Economics and Applied Mathematics from Queens College of the City University of New York.

Frank currently serves on the Board of Trustees to the Solomon R. Guggenheim Foundation and on the Advisory Board to the Hong Kong Life Sciences Society.

Simos Simeonidis, PhD
Co-Chief Executive Officer, Co-Chief Investment Officer

Simos Simeonidis, PhD joined Ally Bridge Group in 2022 and is Co-Chief Executive Officer and Co-Chief Investment Officer. He is also Portfolio Manager for Ally Bridge Group’s public equity strategy. Most recently, Simos was Partner, Senior Managing Director, Co-Head of Research and Portfolio Manager at Sarissa Capital Management, an investment manager focused on shareholder activism in healthcare. Before that, Simos was Managing Director/Senior Biotechnology Analyst at Royal Bank of Canada and spent over a decade covering biopharmaceuticals at several investment banks, including Cowen and Morgan Stanley. Simos began his industry career in Business Development at Novartis. Before moving to industry, Simos was a faculty member at Harvard Medical School. Simos holds a BS in Biology from Loyola University, MA, MPhil and PhD degrees in Molecular Biology from Columbia University, completed his postdoctoral fellowship at Harvard Medical School, and an MBA in Healthcare Management from the Wharton School.

Simos currently serves on the board of Fondation Sante, supporting biomedical research in Greece.

Charles Chon, CFA
Managing Director
Private Equity

Charles Chon joined Ally Bridge Group in 2013 and is a Managing Director for the private equity strategy focused on investments in medical technology. Before joining Ally Bridge Group, Charles was Sector Head for U.S. medical devices research at Stifel Nicolaus, and previously a Senior Equity Research Analyst at Goldman Sachs. Charles began his career at ABN AMRO before moving to Fred Alger Management. Charles holds a BA in Chemistry from Amherst College where he graduated cum laude and received an MBA in Healthcare Management from Boston University. He is a CFA charterholder.

Kevin Reilly
Managing Director
Private Equity

Kevin Reilly joined Ally Bridge Group in 2021 and is a Managing Director, Special Investments, for the private equity strategy focused on transactions across healthcare subsectors. Before joining Ally Bridge Group, Kevin was a Principal at CRG, a healthcare investment management firm providing growth capital to companies through the form of long-term debt and equity. Kevin began his career in the Healthcare Investment Banking Group at Stifel Nicolaus. Kevin holds a BS in Finance and Information Systems from the University of Maryland.

Andrew Pang
Managing Director
Private Equity

Andrew Pang is a Managing Director for Ally Bridge Group’s private equity strategy, leading the firm’s digital health effort and focusing on deal execution in medical devices. Before joining Ally Bridge Group’s predecessor company in 2010, Themes Investment Partners, Andrew worked at InterLeader, a family office in Hong Kong, where he focused on private equity transactions. Andrew began his career at Bank of America in London in the European leveraged buyout group. Andrew holds a BA in Mathematics and Computer Science from the University of Cambridge where he graduated with first class honors.

Reese Yeh
Managing Director
Private Equity

Reese Yeh is a Managing Director for Ally Bridge Group’s private equity strategy focusing on deal execution of transactions and investments in biopharmaceuticals. Before joining Ally Bridge Group’s predecessor company in 2012, Themes Investment Partners, Reese worked at Morgan Stanley where she focused on private equity transactions across Greater China and the Southeast Asia region. Reese holds a BBA in Finance from National Taiwan University.

Andrew Lam, PharmD
Principal
Private Equity

Andrew Lam joined Ally Bridge Group in 2021 and is a Principal, Special Investments, for the private equity strategy focused on therapeutics. Before joining Ally Bridge Group, Andrew was Senior Director of Business Development at Intercept Pharmaceuticals. Before that, Andrew was a Vice President in the Healthcare Investment Banking Group at Jefferies and an equity Research Associate at BMO Capital and Canaccord Genuity. Andrew began his career several biotechnology companies, including Celgene and Shire. Andrew holds a PharmD from Long Island University and received an MBA from Drexel University.

Sebastian Paquette, CFA
Principal
Private Equity

Sebastian Paquette joined Ally Bridge Group in 2021 and is a Principal for the private equity strategy focused on investments in digital health and medical devices. Before joining Ally Bridge Group, Sebastian was the Director of Healthcare at Solid Rock Group. Prior to that, Sebastian founded two healthcare companies focused on surgeon practice restructuring and medical device supply chain efficiency. Sebastian began his career at Goldman Sachs as a Research Analyst. Sebastian holds a BA in Psychology from Boston College. He is a CFA charterholder.

Tinnie Chau, CFA
Vice President
Private Equity

Tinnie Chau joined Ally Bridge Group in 2015 and is a Vice President for the private equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Tinnie was a Manager in the Corporate Finance department of PricewaterhouseCoopers, providing advisory services on M&A transactions across industries with a focus in the healthcare sector. Tinnie holds a BA and MA in Biological Natural Sciences from the University of Cambridge. She is a CFA charterholder.

David Fang, MD, CFA
Vice President
Private Equity

David Fang joined Ally Bridge Group in 2022 and is a Vice President, Special Investments, for the private equity strategy focused on therapeutics. Before joining Ally Bridge Group, David was an Associate Director, Strategy & Business Development, at Alexion Pharmaceuticals and a member of the AstraZeneca Corporate Ventures team (secondment). David began his career as an equity research associate covering biotechnology at SunTrust Robinson Humphrey. David holds a BS in Electrical Engineering from Northwestern University and he received an MD from the University of Michigan Medical School. He is a CFA charterholder.

Keith Lee
Associate
Private Equity

Keith Lee joined Ally Bridge Group in 2022 and is an Associate for the private equity strategy. Before joining Ally Bridge Group, Keith was an Associate in the Healthcare Investment Banking Group at Jefferies. Before that, Keith worked in investment banking at Wedbush PacGrow and Ocean Park Advisors covering biopharma and renewable energy, respectively. Keith began his career as an Analyst in the Investment Consulting Division of Wilshire Associates. Keith holds a BA in Economics and minor in Accounting from the University of California, San Diego where he graduated magna cum laude.

Steven Plachtyna
Associate
Private Equity

Steven Plachtyna joined Ally Bridge Group in 2020 and is an Associate for the private equity strategy focused on investments in medical technology, tools and diagnostics. Before joining Ally Bridge Group, Steven was a Senior Research Associate at Citi Group and Bank of Montreal Capital Markets. Steven began his career at Medtronic. Steven holds a BS in Biomedical Engineering from the University of Connecticut, where he graduated cum laude, and he received a MEng in Biomedical Engineering and an MBA from Cornell University.

Jonathan Wang, CFA, CPA
Associate
Private Equity

Jonathan Wang joined Ally Bridge Group in 2021 and is an Associate for the private equity strategy. Before joining Ally Bridge Group, Jonathan worked as an Investment Manager at Navis Capital Partners. Before that, Jonathan worked in PricewaterhouseCoopers’ Transaction Services division. Jonathan holds an MPhil in Biochemistry from the University of Hong Kong and a BS in Applied Biology and Biotechnology from the Hong Kong Polytechnic University. He is a CFA charterholder and Certified Public Accountant.

Debra Jiang
Analyst
Private Equity

Debra Jiang joined Ally Bridge Group in 2021 and is an Analyst for the private equity strategy. Before joining Ally Bridge Group, Debra was an Analyst in the Healthcare Investment Banking Group at Morgan Stanley. Debra holds a BS in Statistics from Duke University.

Hong Zheng, PhD
Research Analyst
Public Equity

Hong Zheng joined Ally Bridge Group in 2018 and is a Research Analyst for the public equity strategy focused on investments in biopharmaceuticals. Before joining Ally Bridge Group, Hong was a Senior Equity Research Associate at Royal Bank of Canada Capital Markets. Prior to that, Hong was a medicinal chemist at Ra Pharmaceuticals for three years where he led several drug discovery programs. Hong holds a BS in Chemistry from Fudan University and he received a PhD in Chemical Biology from Boston College.

Stephen Mallon, PhD
Research Analyst
Public Equity

Stephen Mallon, PhD joined Ally Bridge Group in 2022 and is a Research Analyst for the public equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Stephen was a Senior Research Associate at Royal Bank of Canada Capital Markets. Prior to that, Stephen was a Senior Research Associate at Chardan Capital Markets. Stephen began his career as an Investment Manager at Triwise Capital. Dr. Mallon holds a BA in Biochemistry from Bowdoin College, and he received a PhD in Microbiology from the University of Chicago.

Evan Zou
Research Analyst
Public Equity

Evan Zou joined Ally Bridge Group in 2022 and is a Research Analyst for the public equity strategy focused on investments in therapeutics. Before joining Ally Bridge Group, Evan was an Associate Director on the Portfolio Intelligence team at BridgeBio Pharma. Evan began his career as an Analyst in the Healthcare Investment Banking Group at Bank of America Securities. Evan holds a BS in Economics from The Wharton School and a BA in Biophysics from the College of Arts and Sciences at the University of Pennsylvania, where he graduated summa cum laude.

Hinsen Au
Senior Fund Accountant
Private Equity

Hinsen Au joined Ally Bridge Group in 2022 and is a Senior Fund Accountant for the private equity strategy. Before joining Ally Bridge Group, Hinsen was as a Senior Fund Accountant at Maples Fund Services and a Fund Services Officer at Alter Domus in Hong Kong. Hinsen began his career as an Accountant at Penske Media Corporation in New York. Hinsen holds a BBA in Accounting from Baruch College, a City University of New York.

Michael Bendetson
Head of Legal, Chief Compliance Officer
Public Equity

Michael Bendetson joined Ally Bridge Group in 2021 and is Head of Legal and Chief Compliance Officer for the public equity strategy. Before joining Ally Bridge Group, Michael was a Capital Markets Associate at Paul, Weiss, Rifkind, Wharton & Garrison LLP. Michael began his career as a Derivatives and Structured Products Associate for Davis Polk & Wardwell LLP. Michael holds a BA in Political Science from Tufts University, where he graduated magna cum laude, and he received a JD from the University of Michigan Law School.

Flora Cai
Head of Compliance
Private Equity

Flora Cai joined Ally Bridge Group in 2021 and is Head of Compliance for the private equity strategy. Before joining Ally Bridge Group, Flora was a Principal of Legal and Compliance at CPE Group where she was responsible for overseeing the compliance function for the entire team, responsible for both USD and RMB denominated private equity and hedge funds. Before that, Flora was a Director and Head of Legal and Compliance at UBS SDIC Asset Management. Flora began her career at Deacons. Flora holds an LLB from Shantou University and an LLM from the University of Hong Kong.

Susanna Chan
Executive Coordinator

Susanna Chan joined Ally Bridge Group in 2022 and is an Executive Coordinator. Before joining Ally Bridge Group, Susanna was an Executive Assistant at ShawKwei & Partners and Steve Leung Design Group. Prior to that, Susanna spent nearly a decade in investment banking administration and research as a Manager at the Carlyle Group and a Research Associate at Morgan Stanley. Susanna began her career as a Business Analyst at Goldman Sachs in Hong Kong. Susanna holds a BCom from The University of British Columbia.

Kelly Cheng, CPA
Vice President
Private Equity

Kelly Cheng joined Ally Bridge Group in 2021 and is a Vice President on the finance team. In this capacity, Kelly is responsible for corporate and general partner-related finance and operations. Before joining Ally Bridge Group, Kelly was a senior member of the Corporate Accounting team at Citadel. Before that, Kelly worked at Bank of America as a legal entity controller. Kelly began her career at PricewaterhouseCoopers and then Deloitte. Kelly holds BCom in Accounting and Economics from the University of New South Wales. She is a Certified Public Accountant.

Amy Herrup, CFA
Head of Business Development and Investor Relations

Amy Herrup joined Ally Bridge Group in 2021 and is Head of Business Development and Investor Relations. Before joining Ally Bridge Group, Amy was a Director in Client Solutions at Capstone Investment Advisors, LLC. Before that, Amy managed investor relations at Varadero Capital, L.P. Amy began her career at Goldman Sachs in the Securities Division. Amy holds a BA in Economics and Mathematical Methods in the Social Sciences from Northwestern University. She is a CFA charterholder.

Daniel Johnson, CPA
Chief Financial Officer
Public Equity

Daniel Johnson joined Ally Bridge Group in 2020 and is Chief Financial Officer for the public equity strategy. Before joining Ally Bridge Group, Daniel held various roles including Head of Finance and Administration at Elenion Capital, CFO/CCO at Castle Ridge Investment Management and COO/CFO/CCO at Trend Capital Management. Daniel began his career as a Senior Associate at Coopers & Lybrand before moving to Morgan Stanley, while also spending several years at Tiger Management. Daniel holds a BS in Accounting from the Pamplin College at Virginia Tech. He is a Certified Public Accountant.

Eric Kwong
Head of Operations
Public Equity

Eric Kwong joined Ally Bridge Group in 2021 and is Head of Operations for the public equity strategy. Before joining Ally Bridge Group, Eric was a Vice President on the Operations and Finance team for Jacobs Asset Management for eight years. Eric began his career at Citigroup as a hedge fund accountant before moving to Vastardis Capital Services as a middle office analyst. Eric holds a BBA in Finance from Baruch College.

Sharon Lam, CPA
Finance Manager
Private Equity

Sharon Lam joined Ally Bridge Group in 2021 and is a Finance Manager for the private equity strategy. Before joining Ally Bridge Group, Sharon was a Finance Manager at Welkin Capital, an Asia-focused growth equity investment firm. Sharon holds a BCom in Accounting from Macquarie University in Australia. She is a Certified Public Accountant.

Autumn Langholz
Executive Coordinator

Autumn Langholz joined Ally Bridge Group in 2022 and is an Executive Coordinator. Before joining Ally Bridge Group, Autumn was an Executive Assistant at Sensiva Health, Target Corporation and Waterstone Capital Management. Autumn has more than 15 years of experience as an Executive Assistant.

Amy Lau
Executive Coordinator

Amy Lau joined Ally Bridge Group in 2021 and is an Executive Coordinator. Before joining Ally Bridge Group, Amy was an Executive Assistant at CPE Group, UBS and Citigroup. Amy has more than 15 years of secretarial experience.

Bowie Pang
Financial Controller
Private Equity

Bowie Pang joined Ally Bridge Group in 2021 and is a Financial Controller for the private equity strategy. Before joining Ally Bridge Group, Bowie was the Financial Controller at Fulcrum Global. Before that, Bowie worked in the private equity and hedge fund investment groups at TR Capital. Bowie began her career with SSG Capital where she spent over eight years working across private equity mid- and back-office functions. Bowie holds a BA in Economics from Loughborough University in England.

Charles Wong, CPA
Chief Financial Officer
Private Equity

Charles Wong joined Ally Bridge Group in 2020 and is Chief Financial Officer for the private equity strategy. Before joining Ally Bridge Group, Charles spent over ten years in alternative asset management and financial services across various roles, including Chief Financial Officer at TR Capital, Vice President in the Finance team at CIitic PE and Financial Controller at DST. Charles began his career as an auditor at Deloitte in both New York and Hong Kong. Charles holds a BBA in Accounting and Finance from the Hong Kong University of Science and Technology and is a Certified Public Accountant.

Kerry Wong
Accounting Officer
Private Equity

Kerry Wong joined Ally Bridge Group in 2021 and is an Accounting Officer on the finance team. In this capacity, Kerry is responsible for corporate and general partner-related finance and operations. Before joining Ally Bridge Group, Kerry was an Accountant at DCP Capital. Kerry holds a BBS from Charles Sturt University in Australia.

Emma Yang
Director of Legal
Private Equity

Emma Yang joined Ally Bridge Group in 2022 and is Director of Legal for the private equity strategy. Before joining Ally Bridge Group, Emma was Head of Legal & Compliance for the Hong Kong office of C.M. Capital Advisors, the financial arm of Cha Group headquartered in Silicon Valley. Before that, Emma held various roles at international law firms including Mayer Brown JSM and King & Wood Mallesons. Emma holds an MCL from the University of Hong Kong and is a PRC qualified lawyer.

Tom Boone

Tom Boone has served as an independent consultant to Ally Bridge Group since 2014. Before co-founding REMD Biotherapeutics, Tom spent 28 years at Amgen and most recently was Global Head of Protein Science. Tom began his career at Amgen with the isolation and cDNA cloning of novel cytokines and growth factors. He later developed proprietary processes used to produce recombinant G-CSF and other therapeutic candidates for clinical application. Tom holds a BS in Genetics and an MS in Soil Science from the University of California, Davis and an MA in Microbiology from the University of California, Los Angeles.

Ryan Chang, MD, PhD

Ryan Chang has served as an independent consultant to Ally Bridge Group since 2014. Ryan is a trained physician scientist who practices internal medicine and hematology/oncology, and his scientific research focuses on developing nanoengineered materials as therapeutics for autoimmune, infectious and oncologic indications. Ryan holds a BS in Biomedical Engineering from the John Hopkins University and received an MD from the University of California, San Francisco (UCSF) School of Medicine as well as a PhD in Bioengineering from the UCSF and University of California, Berkley Joint Graduate Program.

Jennifer King, PhD

Jennifer King has served as an independent consultant to Ally Bridge Group since 2022. Before founding King BioConsulting in 2020, Jennifer worked at Intellia Therapeutics from 2015 to 2019 where she most recently was a Senior Vice President in Business Development. Before that, Jennifer was Senior Director of Business Development at Takeda Pharmaceutical Company Limited (formerly Shire Pharmaceuticals) from 2006 to 2015. Jennifer began her career at Millennium Pharmaceuticals where she held a variety of commercial roles. Jennifer holds a BS in Biology from the Massachusetts Institute of Technology, a PhD in Developmental Biology from the Stanford University School of Medicine, and an MBA from Northeastern University.

Luke Li, MD, PhD

Luke Li has served as an independent consultant to Ally Bridge Group since 2015. Most recently, Luke was Executive Director and Head of Biotherapeutic Technologies at Pfizer where he was actively involved in Pfizer’s global R&D investment and business development for five years. Before that, Luke spent 18 years at Amgen in pharmaceuticals R&D. Luke began his career in academia as a clinical professor at the Washington University School of Medicine. Luke holds an MD and MS in Pharmacology from Fujian Medical University.

Dayu Teng, PhD

Dayu Teng has served as an independent consultant to Ally Bridge Group since its establishment in 2013. Dayu is a post-doctoral researcher at the Institute of Biomedical Engineering at the University of California, San Diego (UCSD). Under the guidance of Dr. Shu Chien, founding chairman of the Institute of Biomedical Engineering at UCSD, Dayu co-founded a company that uses miniaturized high throughput live-cell screening technology to optimize the combinatorial drug therapies for cancer and infectious diseases. Dayu holds a BS, MS and PhD in Bioengineering from the UCSD.

We partner with companies across their entire lifecycle.

Diversified Investment in Global Healthcare Innovation.

Our life science investments span geography and sector, as we seek to identify those firms that hold the potential to transform healthcare for society in the years to come.

All
Private Equity
Public Equity

Aerin Medical

Aerin Medical is medical technology company focused on the ear, nose and throat market providing non-invasive solutions for the treatment of chronic nasal conditions.

View Site

Arbor Biotechnologies

Arbor Biotechnologies is a biotechnology company that aims to discover and develop the next generation of genetic medicines based on wholly owned genomic editors discovered from its machine learning/AI driven discovery platform.

View Site

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing direct anti-viral medicines to treat infectious diseases. Atea completed its IPO on the Nasdaq stock market in October 2020.

View Site

BenevolentAI

BenevolentAI is a clinical-stage drug discovery company seeking to combine artificial intelligence and machine learning with science to decipher complex disease biology, generate new insights and discover more effective medicines. The company’s computational R&D platform spans each step of the drug discovery process, with a focus on novel disease targets discovery.

View Site

Cerevel Therapeutics

Cerevel Therapeutics is a clinical-stage biopharmaceutical company developing drugs for neurological diseases. The company is adopting an understanding of the biology and central nervous system receptors with advanced chemistry to discover and develop these therapeutics.

View Site

Ceribell

Ceribell is a medical device and artificial intelligence data analytics platform that deploys a cloud-linked, portable electroencephalogram (“EEG”) headband to facilitate rapid point-of-care diagnosis and treatment of life threatening neurological conditions.

View Site

CMR Surgical

CMR Surgical is a medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot. The company is committed to working with surgeons, surgical teams and hospital partners to provide a tool to redefine the surgical robotics market using technology that can improve surgical care as well as make robotic minimal access surgery universally accessible and affordable.

View Site

Cogent Biosciences

Cogent Biosciences is a biotechnology company that develops precision therapeutics to treat patients with unmet medical needs. The lead program, bezuclastinib, is a selective KIT inhibitor that is being tested in clinical trials for Systemic Mastocytosis and Gastrointestinal Stromal Tumor.

View Site

Elligo Health Research

Elligo Health Research uses electronic health records to help ensure that patients have access to clinical research as a possible care option. Powered by their “Goes Direct” approach and IntElligo Research Stack clinical technology, the company engages physicians and patients to help develop new pharmaceutical, biotechnology, medical device and diagnostic products.

View Site

Endeavor BioMedicines

Endeavor BioMedicines is a clinical-stage precision medicine company that targets the core drivers of multiple terminal diseases, including oncology and fibrosis. The Company seeks to combine advancements in technology with an evolving understanding of terminal diseases in order to develop best-in-class medicines with the potential to reverse the most severe health conditions.

View Site

Goldfinch Bio

Goldfinch Bio is a precision medicine company focused on delivering disease-modifying medicines to people with kidney disease. The company’s lead program, GFB-887, is being studied in a variety of kidney diseases.

View Site

Imperative Care

Imperative Care is a vascular technology company focused on developing the next generation of solutions to address needs for stroke patients. The company has two 510(k) cleared product platforms and a stroke technology development pipeline.

View Site

Isoplexis

IsoPlexis is a life science tools company that provides a proteomics system to reveal biological activity at the single-cell level. The company’s flagship system, IsoLight, provides an end-to-end solution to reveal a more complete view of protein function and linking cellular function to treatment response, disease progression and patient outcomes.

View Site

Luoxin Pharmaceuticals Group

Luoxin Pharmaceuticals Group is a healthcare conglomerate engaged in the research and development, manufacturing and sale of chemical medicine.

View Site

Mainstay Medical

Mainstay Medical is a medical device company focused on commercializing an implantable Restorative Neurostimulation system, ReActiv8, for people with disabling mechanical and chronic low back pain.

View Site

Mavrik Dental Systems

Mavrik Dental Systems focuses on developing proprietary technology for the in-office dental treatment market. The company’s Thera-Oral delivery platform and Thera-Smile whitening solution are automated systems that seek to help provide clinicians with efficient treatment plans.

View Site

MedAvail

MedAvail is a technology-enabled pharmacy organization that provides in-clinic pharmacy services through its proprietary robotic dispensing platform and home delivery operations to Medicare clinics. The company seeks to help physicians and patients to optimize drug adherence, resulting in better health outcomes.

View Site

Mission Bio

Mission Bio is a life science tools company focused on single cell genomics, proteomics and multi-omics solutions for oncology study and cell and gene therapy development.

View Site

Nautilus Biotechnology

Nautilus Biotechnology is developing a proteomics platform enabling the detection of proteins with single molecule sensitivity. The company aims to accelerate science research, improve the success rate of therapeutic development and enhance opportunities for personalized and predictive medicine.

View Site

Nikang Therapeutics

Nikang Therapeutics is a clinical-stage biotechnology company focus on the development of small molecule medicines for the treatment of cancers. The company is adopting target selection and medicinal chemistry approaches to develop precision oncology drugs.

View Site

Nuvation Bio

Nuvation Bio is a clinical-stage biopharmaceutical company developing oncology medicines targeting critical pathways in cancer biology. The company has a pipeline with multiple wholly owned programs, the lead program being a selective BET inhibitor.

View Site

Pulmonx

Pulmonx focuses on minimally invasive treatments for severe lung disease. The company’s platforms are designed to assess and treat patients with severe emphysema and chronic obstructive pulmonary disease who, despite medical management, are still symptomatic. Pulmonx completed its IPO on the Nasdaq stock market in October 2020.

View Site

Quantum Surgical

Quantum Surgical is a medical robotic company developing a solution dedicated to minimally invasive liver cancer treatment. The company aims to help physicians throughout a patient’s continuum of care, including pre-operative planning, intra-operative ablation treatment and post-operative care.

View Site

RapidMicro Biosystems

RapidMicro Biosystems is a provider of the fully automated, high-volume and secure Microbial Quality Control solution for pharmaceutical manufacturing (primary focus), food and beverage safety, personal care manufacturing, environmental water sector, industrial processing and diagnostics. The company completed its IPO on the Nasdaq stock market in July 2021.

View Site

RefleXion Medical

RefleXion Medical is a commercial stage company developing a biology-guided radiotherapy system, which allows for treatment of multiple tumors in the same treatment session in cancers that have metastasized.

View Site

Shoreline Biosciences

Shoreline Biosciences is a biotechnology company developing genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer and macrophage immunotherapies for the treatment of cancer.

View Site

Sonoma Biotherapeutics

Sonoma Biotherapeutics focuses on Treg cell therapies for autoimmune and degenerative diseases. Using genome editing and target-specific cell therapy, the company works to discover and develop disease modifying and curative therapies across the spectrum of Treg cell therapeutic capabilities.

View Site

Strateos

Strateos designs, builds and operates closed loop robotic cloud labs allowing researchers to run and control automated chemical and biological workflows.

View Site

Syapse

Syapse aims to use real-world evidence brought by Syapse Learning Health Network to improve the outcomes of cancer patients through improved precision medicine. Syapse and its partners are working towards a future where all cancer patients have access to the quality of care they need.

View Site

Transcarent

Transcarent is a digital health company focused on employee health benefits, aiming to improve the both the quality of care and reduce inefficiency in the existing healthcare system.

View Site

Ultivue

Ultivue is a spatial biology company that provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. The company’s proprietary multiplex immunofluorescence technology enables exploration and interrogation of tissue samples for precision medicine research to accelerate biomarker discovery and drug development programs.

View Site

Vida Health

Vida Health is a digital management company focused on developing a proprietary technology platform that provides chronic disease, wellness and mental/behavioral health management solutions.

View Site

Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company focused on developing new treatments for patients with rare diseases. The company leverages validated biology and target/pathway with the clinical development strategy in order to deliver improvements in access, quality of life and potentially efficacy. The lead program, VRDN-001, is an anti-IGF-1R antibody in development of thyroid eye disease.

View Site

WuXi AppTec

WuXi AppTec provides a portfolio of R&D and manufacturing services that enable companies in the global pharmaceutical, biotechnology and medical device industries to advance discoveries and deliver treatments to patients. WuXi AppTec helps its partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec completed its IPO on the Hong Kong stock exchange in December 2018.

View Site

WuXi Biologics

WuXi Biologics is a global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a one-stop service offering and strong value proposition to its global clients. WuXi Biologics completed its IPO on the Hong Kong stock exchange in June 2017.

View Site

We seek to leverage local relationships across the global marketplace.

Making an Impact.

  • All
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
21
September 2022
Private Equity Portfolio News: Ceribell Closes $50 Million Equity Financing Round Led by Ally Bridge Group

Additional financing strengthens Ceribell’s shareholder base and provides capital to support commercial expansion and further development of the company’s first-of-its kind Ceribell Rapid Response EEG System SUNNYVALE, Calif., September 21,…

21
July 2022
Simos Simeonidis, PhD Joins Ally Bridge Group as CO-CEO and CO-CIO

New York, New York–(PR Newswire)–Ally Bridge Group (the “Firm”) is pleased to announce Simos Simeonidis, PhD joined the Firm as Co-Chief Executive Officer and Co-Chief Investment Officer based in New…

16
June 2022
Private Equity Portfolio News: Aerin Medical Secures $60 Million in Equity Financing

Ally Bridge Group joins existing syndicate of KCK MedTech, Questa Capital and OrbiMed. Sunnyvale, CA – June 16, 2022 – Aerin Medical Inc., a company dedicated to providing Ear, Nose…

10
March 2022
Solomon R. Guggenheim Foundation Elects Frank Yu to the Board of Trustees

New York, NY—J. Tomilson Hill, Chair, and Wendy Fisher, President, Solomon R. Guggenheim Foundation, today announced that Frank Yu has been elected to the Board of Trustees. In a joint…

24
February 2022
Biotech IPOs Slow After Record-Breaking 2021

Investors say industry’s fundamentals remain strong. By Brian Gormley (WWW.WSJ.COM)–Ini­tial pub­lic of­fer­ings by biotech­nol­ogy com­pa­nies are slow­ing af­ter two record-set­ting years as the poor per­formance of some re­cent IPOs com­bined with eco­nomic and geopo­lit­i­cal un­cer­tain-ties have cooled in­ter­est…

7
February 2022
Private Equity Portfolio News: Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline

Three oncology and fibrotic disease programs in clinical development by end of 2022 SAN DIEGO (BUSINESS WIRE) — Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal…

11
January 2022
Private Equity Portfolio News: Transcarent Raises $200 Million in Series Funding Highlighting Growing Demand for a Different Health and Care Experience Aligned with the Needs of Self-Insured Employers

Led by Kinnevik and Human Capital and joined by Ally Bridge Group, General Catalyst, 7wireVentures and existing Transcarent investors Leading health systems Northwell Health, Intermountain Healthcare, and Rush University Medical…

9
November 2021
Private Equity Portfolio News: Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics

The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Massachusetts…

2
November 2021
Private Equity Portfolio News: Shoreline Biosciences Announces $140 million Financing to Advance Pipeline of Next Generation Cell Immunotherapies

Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities SAN DIEGO, Nov. 2, 2021 /PRNewswire/…

19
October 2021
Private Equity Portfolio News: Quantum Surgical Secures €40 million to Support the Commercial Launch of Epione

Montpellier, France, October 19th, 2021 – Quantum Surgical, an innovative medical robotic company, announced today that it has secured €40 million (US$48 million) of financing. Led by existing key investor Ally…

23
September 2021
Private Equity Portfolio News: Morgan Stanley Expansion Capital and Ally Bridge Group Lead $135 million Investment in Elligo

Proceeds Used to Acquire ClinEdge and Invest Further in Technology & Data Platform September 23, 2021 12:30 PM Eastern Daylight Time SAN FRANCISCO–(BUSINESS WIRE)–Morgan Stanley Expansion Capital and Ally Bridge…

4
August 2021
Private Equity Portfolio News: Sonoma Biotherapeutics Raises $265 million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases

Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary regulatory T cell (Treg) therapy and effector T cell (Teff) conditioning Series B financing comprised of…

15
July 2021
Private Equity Portfolio News: Imperative Care Raises $260 million to Advance Innovations that Elevate Stroke Care

Imperative Care to Create Strategic Network of Wholly Owned Development Subsidiaries in Areas of Synergy, Starting with Acquisition of Truvic Medical, Inc., a Peripheral Thrombectomy Innovator July 15, 2021 08:00…

28
June 2021
Private Equity Portfolio News: CMR Surgical Raises $600 million in Series D Financing, Led by SoftBank Vision Fund 2 and Co-Led by Ally Bridge Group

June 28, 2021 07:00 ET | Source: CMR Surgical Funding fully supports the accelerated continued global expansion and commercial scale up of the business Financing round led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group The largest ever…

6
May 2021
Private Equity Portfolio News: Vida Health Raises $110 million in Series D Round Led By Atlantic, Centene and AXA Venture Partners

New capital to help Vida continue to scale virtual chronic mental and physical healthcare services after tripling revenue in 2020 Led by General Atlantic, the $110M Series D fundraise will…

27
April 2021
Public Equity Portfolio News: Ultivue Announces $50 million Financing Round

April 27, 2021 10:07 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE) –Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional…

16
March 2021
Private Equity and Public Equity Portfolio News: RapidMicro Biosystems Raises $81 million to Continue Global Expansion of Automated Pharmaceutical QC Platform to Improve Data Integrity and Safety in Biologics, Vaccines and Cell and Gene Therapy Manufacturing

LOWELL, Mass., March 16, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc., the leading provider of data integrity and automation technology for microbial detection in biopharmaceutical manufacturing, today announced the…

2
March 2021
Private Equity Portfolio News: RefleXion Adds Ally Bridge Group to Investor Syndicate

Expands Series D financing by $40M March 02, 2021 10:00 AM Eastern Standard Time HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for…

16
February 2021
Private Equity Portfolio News: Ally Bridge Group Co-leads Mainstay Medical’s $108 Million Equity Financing

Funding to support U.S. commercial launch and global expansion February 16, 2021 08:00 AM Eastern Standard Time DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the closing…

8
February 2021
Public Equity Portfolio News: Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq through Merger with Arya Sciences Acquisition Corp III

Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under…

2
February 2021
Private Equity Portfolio News: Syapse Announces $68 million Strategic Investment with Ally Bridge Group and Northpond Ventures to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network

February 02, 2021 10:00 ET — Financing to support expanded partnering opportunities with life sciences, health systems, regulators and molecular labs — — Syapse committed to delivering real-world insights to…

18
November 2020
Private Equity and Public Equity Portfolio News: MedAvail Completes $84 million Private Placement Led by Ally Bridge Group

November 18, 2020 06:13 PM Eastern Standard Time MISSISSAUGA, Ontario & PHOENIX–(BUSINESS WIRE)–MedAvail Holdings, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds automated pharmacy services directly into clinics and…

28
October 2020
Public Equity Portfolio News: miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

Acquisition includes clinical stage anti-IGF–1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED). Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan…

21
October 2020
Public Equity Portfolio News: Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development

NEW YORK – – October 21, 2020 – Nuvation Bio, Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in…

30
August 2020
Private Equity Portfolio News: Biotechs Tap Growing US Government Support

Federal funding for dementia and Alzheimer’s studies has surged, as venture funding focuses on other diseases Aug 20, 2020 Wall Street Journal Alzheon Inc. will be holding Phase 3 clinical…

30
July 2020
Public Equity Portfolio News: Cerevel Therapeutics and Arya Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development

July 30, 2020 07:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Cerevel Therapeutics, Inc. (“Cerevel Therapeutics”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Arya…

6
July 2020
Private Equity Portfolio News: Unum Therapeutics Inc. Announces Acquisition of Kiq LLC

CAMBRIDGE, Mass. and PHILADELPHIA, July 6, 2020 /PRNewswire/ — Unum Therapeutics Inc. (“Unum”) (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announced it has completed the acquisition of Kiq LLC (“Kiq”),…

8
June 2020
Private Equity Portfolio News: World Premier for Quantum Surgical’s Medical Robot at Montpellier University Hospital

Montpellier, France, June 8, 2020 – On June 4, 2020, Professor Boris GUIU and his team at Montpellier University Hospital (France) successfully treated a 56-year-old patient with liver tumor using…

20
May 2020
Private Equity Portfolio News: RapidMicro Biosystems Raises $120 million to Accelerate Global Expansion of Contaminant Testing Platform for Pharmaceutical and Vaccine Manufacturing

Proceeds will enable the company to meet growing demand for its automated microbial detection platform, currently used by a majority of the top 20 global biopharmaceutical companies, and support new…

20
May 2020
Public Equity Portfolio News: Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 million Financing

May 20, 2020 06:00 ET | Source: Atea Pharmaceuticals, Inc. Proceeds to support the clinical development of Atea’s oral, direct acting antiviral medicine for COVID-19, in addition to advancing its diverse pipeline of…

6
May 2020
Private Equity Portfolio News: Ally Bridge Group Leads Pulmonx’s $66 million Financing to Support Commercial Acceleration of the Zephyr Valve System

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group,…

30
April 2020
Private Equity Portfolio News: Ally Bridge Group Leads Vida Health’s $25 million Financing to Scale Network and Meet Increased Demand for Virtual Care

San Francisco, April 30, 2020 — Virtual healthcare platform, Vida Health, announced today that it raised $25 million in new funding to meet the increased demand for mental and physical…

18
February 2020
Private Equity Portfolio News: Ally Bridge Group Leads $30 million Investment in Israel’s Mavrik Dental

JERUSALEM, Feb 18 (Reuters) – Israel’s Mavrik Dental Systems has raised $30 million in a funding round led by life sciences investment firm Ally Bridge Group (ABG), the companies said…

11
December 2019
Private Equity Portfolio News: Ally Bridge Group Co-leads Imperative Care’s $85 million Series C Financing

CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that it has completed the initial closing of a Series C financing of $85 million to support the commercial launch of the company’s…

3
December 2019
Private Equity Portfolio News: Ally Bridge Group Leads Venclose’s $27 million Series C Funding

SAN JOSE, Calif., Dec. 3, 2019 /PRNewswire/ — Venclose, Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease, today announced it has closed its Series C…

9
May 2019
Private Equity Portfolio News: Pulmonx Closes $65 million Financing and Adds Chief Financial Officer

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65 million equity financing and the hiring of Derrick…

4
April 2019
Private Equity Portfolio News: Ally Bridge Group, LifeTech Scientific and Quantum Surgical Announce Three-Way China Joint Venture to Develop Innovative Surgical Robot for the Treatment of Liver Cancer 2019

HONG KONG, SHENZHEN, China, and Montpellier, France, April 4, 2019 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border life science investment group, announced today that it has entered into…

8
December 2018
Private Equity Portfolio News: WuXi AppTec Successfully Prices Hong Kong Offering in Stormy Market

BioCentury – Dec 8, 2018 Despite global trade headwinds and a choppy market for biopharma stocks in China, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) successfully price its Hong Kong listing…

3
December 2018
Private Equity Portfolio News: TESARO Reaches Agreement to be Acquired by GSK

LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire…

18
September 2018
Private Equity Portfolio News: WuXi AppTec Said to File for $1+ billion Hong Kong Offering

September 18, 2018, Bloomberg Report WuXi AppTec Co., the Chinese contract medical researcher, has submitted an application for a Hong Kong share sale, according to people with knowledge of the…

11
July 2018
12 Top China VCs You Need to Know Who Are Making a Transpacific Splash

  Money is rushing into biotech at breakneck speed this year, and one part of the globe is accounting for much of the uptick: China. VC deals were teeming with…

5
July 2018
Private Equity Portfolio News: Chinese Sovereign Wealth Fund Backs LinkDoc’s $151 million Series D

Deal Street Asia / Jul 5, 2018 China Investment Corporation (CIC), a sovereign wealth fund has participated in a RMB1 billion (US$151 million) series D round in Beijing-based oncology, big data…

29
June 2018
Private Equity Portfolio News: I-Mab Successfully Raised $220 million in Series C

SHANGHAI, June 29, 2018 /PRNewswire/ — I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for USD…

3
June 2018
Private Equity Portfolio News: Ally Bridge Expands Early-Stage Cancer Solutions with Investment in Quantum Surgical

HONG KONG and MONTPELLIER, France, June 3, 2018 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading cross-border life science investment group, has completed a Series A investment, as the first…

21
May 2018
Private Equity Portfolio News: GRAIL Announces $300 million Raised in Oversubscribed Series C Financing

MENLO PARK, Calif. & HONG KONG–(BUSINESS WIRE) — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced it has raised…

18
May 2018
China Comes to Europe

CHINESE INVESTORS ARE LOOKING TO EUROPE FOR INNOVATION AT ATTRACTIVE PRICES BY STEPHEN HANSEN, ASSOCIATE EDITOR The historically underfunded European biotech sector is in the early stages of tapping into…

8
May 2018
Private Equity Portfolio News: WuXi AppTec Prices A-Share IPO

Hong Kong and Shanghai, May 8, 2018 / BioCentury / – – Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of…

29
April 2018
Private Equity Portfolio News: Innovent Announced $150 million Series E

ChinaBio Today Report / Apr 29, 2018 Innovent of Suzhou announced its series E financing of $150 million. Capital Group Private Markets (CGPM) is leading this investment with $90 million,…

27
March 2018
Private Equity Portfolio News: Hua Medicine Raises $117.4 Million in Series D & Series E Financing

Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of…

7
January 2018
Private Equity Portfolio News: Ally Bridge Group and LifeTech Scientific Form China-Global Medtech Investment and Operating Partnership

Hong Kong, Shenzhen and San Francisco, January 7, 2018 – Ally Bridge Group (“ABG”), a global healthcare-focused investment firm, has entered into a strategic partnership with LifeTech Scientific Corporation (SEHK:…

28
August 2017
Private Equity Portfolio News: Synlogic Completes Merger with Mirna Therapeutics

CAMBRIDGE, Mass. & AUSTIN, Texas–(BUSINESS WIRE)–Aug. 28, 2017– Synlogic, Inc. and Mirna Therapeutics, Inc. today announced that the proposed merger of the two companies has closed following the approval of…

15
June 2017
Private Equity Portfolio News: PE-backed WuXi Biologics Completes Hong Kong Re-listing

WuXi Biologics, a Chinese contract R&D services provider to the global pharmaceutical industry that was taken private by a PE-backed consortium in late 2015, gained 38% on its Hong Kong…

25
May 2017
Ally Bridge Group Reaches ‘Inflection Point’ with WuXi IPOs

Ally Bridge, the healthcare investment group that whisked Shanghai-based Wuxi Pharmatech from under the noses of established global private equity firms in 2015, is “reaching an inflection point”, according to…

24
May 2017
Private Equity Portfolio News: WuXi Biologics, WuXi AppTech’s IPO Could Benefit from Scarcity Value – Ally Bridge Founder Frank Yu

 Wuxi Biologics has ‘scarcity value’, worth 10% to 15% of group  Future HK IPO of Shandong Luoxin is possible The listings of Wuxi Biologics in Hong Kong and the remainder of WuxiPharmatech‘s assets in China will benefit from their…

16
March 2017
Private Equity Portfolio News: Aerpio Pharmaceuticals Raises $40 million

Aerpio Pharmaceuticals, Inc. (the “Company”), a biopharmaceuticalcompany focused on advancing first-in-class treatments for ocular diseases, today announced thesuccessful completion of its reverse merger transaction with Aerpio Therapeutics, Inc. (“Aerpio”) and…

15
August 2016
How Ally Bridge Group Expects to Build on Top of WuXi Arbitrage Play

China’s Ally Bridge Group hit the investment world’s radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first…

3
May 2016
Building a Global “Bridge” for Life Science Innovation

By Hui Cai, VP of Corporate Alliances at WuXi AppTec (@HuiCai2) As the globalization of healthcare expands, Frank Yu and his team at Ally Bridge Group continue to differentiate themselves in…

19
April 2016
Five Questions for Ally Bridge Group’s Founder Frank Yu

Frank Yu, founder of healthcare-focused investment firm Ally Bridge Group and formerly head of China Investments at Och-Ziff Capital Management, answers five questions in this video interview with Nina Xiang,…

23
March 2016
Private Equity Portfolio News: Ally Bridge Group Keeps Cash Flowing in $155 million Private Placement in TESARO

Hong Kong-based Ally Bridge Group took a hand in a $155 million placement in immuno-oncology biotech Tesaro ($TSRO), joining a funding round led by Kleiner Perkins along with New Enterprise…

14
August 2015
Private Equity Portfolio News: WuXi PharmaTech Enters Into Definitive Merger Agreement

SHANGHAI, Aug. 14, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (“WuXi” or the “Company”) (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device…

30
April 2015
Private Equity Portfolio News: WuXi PharmaTech Announces Receipt of Proposal

SHANGHAI, April 30, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (“WuXi” or the “Company“) (NYSE: WX), a leading global contract R&D services provider, today announced that its board of directors has received a…

Get in Touch.

Ally Bridge Group (NY) LLC
430 Park Avenue, 12th Floor
New York, New York 10022

Ally Bridge Group (HK) Limited
Gloucester Tower, The Landmark, 30th Floor
15 Queen’s Road Central, Hong Kong

For all investor inquiries, please reach out to investor.relations@ally-bridge.com.

Disclosure.

1.0 Terms of Use
Ally Bridge Group and its affiliates (together, “Ally Bridge”, “we”, or “us”) welcome you to our website (along with its accounts, pages and applications, collectively, the “Site”). By accessing, browsing and/or using the Site, you acknowledge that you have read and understand, and agree to be bound by the following terms and conditions of use and all disclaimers and terms and conditions that appear on the Site now, as well as the privacy policy of the Ally Bridge Site (the “Privacy Policy”, as set out in section 2 below, and together with the terms and conditions of use and all disclaimers and terms and conditions that appear on the Site, the “Terms”). This Site is offered to you conditioned on your acceptance without modification of the Terms contained herein. These Terms are a contract between you and Ally Bridge (the “Agreement”) and govern your visit to and use of the Site. This Agreement may be updated by us at any time. You should visit this page periodically to review the Agreement for changes. Your use of the Site, and your continued use of the Site after any such updates or modifications, constitutes your acceptance of the Terms. If you do not accept this Agreement, or if you cannot form a legally binding contract, you do not have permission to access, browse or use the Site and your sole and exclusive remedy is to discontinue using the Site.

1.1 Ownership of Materials on Site
All the material displayed on and/or accessible through the Site, including without limitation, software, text, graphics, charts, information, arrangements of information, images, articles, reports, presentations, screens, user documentation, user interfaces, related software and other material (the “Content”), is the property of Ally Bridge or others accessible via the Site and shall remain the exclusive property of Ally Bridge and its licensors, as the case may be. All Content is protected by international copyright and other laws. Nothing contained on the Site should be construed as granting, by implication, estoppel or otherwise, any license or right to use any Content without the written permission of Ally Bridge or such other party that may own the applicable Content. Nothing in this Agreement shall constitute a waiver of any trademark, copyright or other intellectual property rights. Ally Bridge reserves the right to enforce its intellectual property rights to the full extent of the law.

1.2 Restrictions on Use
The Site is for your personal education and non-commercial use. You may download or print out a hard copy of individual pages and/or sections of the Site, provided that you do not remove any copyright or other proprietary notices. Any downloading or otherwise copying from the Site will not transfer title to any software or material to you. You must not modify the paper or digital copies of any materials you have printed off or downloaded in any way, and you must not use any illustrations, photographs, video or audio sequences or any graphics separately from any accompanying text. You may not reproduce (in whole or in part), transmit (by electronic means or otherwise), modify, copy, distribute, publish, license, create derivative works from, link into, sell or use for any public or commercial purpose or in any way exploit the whole or any part of the Site without the prior written permission of Ally Bridge. We reserve all rights with respect to copyright and trademark ownership of all material on the Site. You may not use the Site in any way that is fraudulent, unlawful or violates any existing agreements you may have with Ally Bridge. Any unauthorized use of the Site or misuse of any information posted to the Site is strictly prohibited. You agree that you shall not place false or misleading information on the Site or upload any computer programs, including but not limited to viruses, Trojan horses or worms that may interfere with the proper operation of our sites. Ally Bridge may, in its sole discretion, terminate your use of the Site at any time. Ally Bridge reserves the right to change, suspend or discontinue all or any aspects of our sites at any time without prior notice.

1.3 Investment Disclaimer
This Site is for informational purposes only and should not be construed as a solicitation or offer, or recommendation to acquire or dispose of any investment or to engage in any other transaction. We do not provide investment, accounting, tax, legal or other specialist advice through the Site. If you would like investment, accounting, tax or legal advice, you should consult with your own financial advisors, accountants or attorneys regarding your individual circumstances and needs. You agree that Ally Bridge is not liable for any action you take or decision you make in reliance on any Content. Ally Bridge will not treat users of the Site as its partners, clients, customers or investors by virtue of their accessing the Site.

1.4 Performance Information
The information contained on or comments expressed on the Site may include certain prior indications of past investment performance. In considering such prior performance information, you should bear in mind that past performance is not indicative of future results and there can be no assurance that any investment will, or is likely to, achieve comparable results to those achieved in the past, or that significant losses will be avoided. Any projections, market outlooks or analyses, estimates and/or statements of opinions provided on the Site are forward-looking statements and are inherently uncertain and are based on a number of assumptions. Other events which were not taken into account may occur and may significantly affect investment returns or performance. You should carefully review information regarding any such analyses and underlying assumptions. Any reference to Assets Under Management or AUM used on the Site reflect the combined Assets Under Management of Ally Bridge investment advisors as of the specific time indicated. ANY PROJECTIONS, OUTLOOKS OR ASSUMPTIONS CONTAINED IN THE INFORMATION ON THIS WEBSITE SHOULD NOT BE CONSTRUED TO BE INDICATIVE OF THE ACTUAL EVENTS WHICH WILL OCCUR.

1.5 No Reliance
While we use reasonable efforts to obtain information from sources which we believe to be reliable, and to update the information on the Site, we make no representation that the information or opinions contained in the Site are accurate, reliable, updated or complete. The information and opinions contained in the Site are provided by us for personal use and informational purposes only and are subject to change without notice. Nothing contained on the Site constitutes investment, legal, tax or other advice nor is it to be relied on in making an investment or other decision.

1.6 Third-Party Links
We may provide links from the Site to websites operated by third parties who may or may not be affiliated with Ally Bridge. We have not reviewed unaffiliated sites linked to the Site, and we do not endorse, have any responsibility for or make any representations about, any other sites, including their products and services, content, communications, opinions and website use policies. We cannot and do not make any express or implied warranty about the accuracy, copyright compliance, legality, merchantability or any other aspect of the content of such links. The use of third party websites is entirely at your own risk. By accessing these links, you acknowledge that such other sites or locations are not under the control of Ally Bridge and that Ally Bridge does not endorse the content of such sites and locations, and you agree that Ally Bridge shall not be responsible for any information or additional links found at such site or location, or for your use of such information.

1.7 Local Regulatory Restrictions
This Site is not directed to any person in any jurisdiction where (for any reason) the publication or availability of this website is prohibited, and persons in respect of whom such prohibitions apply must not access this website. Those who choose to access the Site from other locations do so at their own initiative and are responsible for compliance with local laws.

Given the global nature of the internet, this Site may be accessed by visitors residing outside of the United States. Ally Bridge makes no representations or warranties that this Site is appropriate or available for use in countries outside of the United States, or that services discussed on this Site are available or appropriate for sale or use in all jurisdictions, or by all counterparties. Visitors who choose to access this Site from outside of the United States do so at their own initiative and are responsible for compliance with any and all local laws and regulations that may apply to such access. You may not use or export the information or materials in violation of U.S. export laws and regulations.

1.8 No warranty and limitations of liability
Ally Bridge, its affiliates and their respective officers, directors, managers, partners, members, shareholders, employees, affiliates and agents (collectively “Related Persons”) make no representations or warranties and specifically disclaim any and all warranties of any kind, express or implied, with respect to the Site and the Content, including any representations or warranties with respect to merchantability, fitness for a particular purpose, title, non-infringement, availability, security, accuracy, freedom from viruses or malware, completeness, timeliness, functionality, reliability, sequencing or speed of delivery. Your use of the Site and the Content is on an “as is” and “as available” basis. If you are not able to use or access the Site, or any websites linked to through the Site, Ally Bridge is not responsible for any problems that this causes.

In no event shall Ally Bridge, its affiliates or their Related Persons be liable to any party for any claims, liabilities, losses, costs or damages under any theory, including but not limited to any direct, indirect, punitive, special, incidental, or consequential damages arising out of in connection with any access, use (or inability to use) or distribution of the Site, or any Content therein, even if Ally Bridge or their related persons are advised of the possibility of such damages, losses or expenses. You acknowledge and agree that you may not bring a claim against Ally Bridge relating to your use of the Site after more than one year has passed since the event occurred that gave rise to the claim, while there is no such limitation on Ally Bridge’s right to bring claims against you. You acknowledge and agree that the disclaimers, including the warranty disclaimers, and the liability and remedy limitations in this Agreement are material terms of this Agreement and that they have been taken into account in the decision by Ally Bridge to provide the Site hereunder.

1.9 Governing Law
The Site is made available to you from the State of New York. The laws of New York will govern this Agreement (including any disputes concerning or related to this Agreement). The courts of New York have exclusive jurisdiction to settle any dispute, controversy or claim arising from or connected with this Agreement. Notwithstanding the foregoing, you expressly acknowledge and agree that Ally Bridge may seek injunctive or other appropriate relief in any court of competent jurisdiction and you consent to exclusive jurisdiction and venue in such courts. This Agreement is a personal agreement between you and Ally Bridge, and no one shall be a third party beneficiary to this Agreement. If any provision of this Agreement shall be unlawful, void, or for any reason unenforceable, then that provision shall be deemed severable from this Agreement, shall be enforced to the fullest extent allowed by law as to effect the intention of the parties, and shall not affect the validity and enforceability of any remaining provisions.

2.0 Privacy Policy
This privacy policy (the “Privacy Policy”) applies to your access and use of the Site and use of the Ally Bridge websites and/or other online programs, or the materials, software and content available in or through them (altogether, the “Site”). An important part of our commitment to you is our respect for your privacy as a user of the Site. This Privacy Policy seeks to help you understand whether and how we collect information about you when you visit the Site, and how we use such information.

Your visit to the Site is subject to this Privacy Policy and our Terms. By visiting, using and/or downloading any information available on the Site, you agree to this Privacy Policy and our Terms, which may be updated by us at any time, and consent to all actions that we take with respect to your data consistent with this Privacy Policy and our Terms. If you do not agree to this Privacy Policy or the Terms, you are instructed not to use this website. If we update our Privacy Policy, we will post the updated Privacy Policy here. Any such changes will be effective upon posting. You should visit this page periodically to review the Privacy Policy for changes. This privacy policy does not apply to information Ally Bridge collects offline or through email.

2.1 Information We Collect About You
We may make sensitive permissions requests and/or automatically collect information about your computer, tablet, mobile device or other electronic device when you visit our Site. This information may include your Internet Protocol (IP) address, Internet Service Provider (ISP), domain name, browser type, date and time of your request and information. We do not employ cookies. If you voluntarily submit information to our website, for example, in a request for general information or through the submission of a business proposal, we may record and use any personally identifiable information, financial information, authentication information, phonebook or contact data and sensitive device data for reasonable business purposes including, but not limited to, fulfilling your request. You acknowledge that you assume all responsibility related to the security, privacy and risks inherent in sending any content over the Internet.

2.2 Use of Information We Collect
Ally Bridge does not disclose any nonpublic personally identifiable information about its Site users to any nonaffiliated third party, except as set forth below.

We may use or disclose certain personally identifiable information we collect about you when you visit and browse the Site as part of our normal business operations, or to send you administrative communications either about your interactions with us or about features of the Site, including any future changes to this Privacy Policy. We may also use service providers to facilitate our services or platform functions on our behalf. These companies and individuals may have access to your personally identifiable information, as needed to perform their functions, but may not use it for another purpose. We will use or disclose personally identifiable information when we believe that such disclosures are required by law, regulation, legal process, subpoena, document request or governmental request, and we may disclose your communications and activities on the Site in response to requests by any government agency. Ally Bridge reserves the right to use any personally identifiable information in any manner permitted by law.

2.3 Protection of Information
We endeavor to protect your personally identifiable information. We use technical, administrative and physical methods to maintain the integrity and security of our databases, including firewalls. This website is not absolutely protected against unauthorized third parties. You acknowledge that any information provided through the Internet may be potentially accessed by unauthorized third parties. Although We will make reasonable efforts to protect the privacy of users of the Site, no guarantee can be made that unauthorized third parties will not access the information contained on the Site. You acknowledge that Ally Bridge is not responsible for notifying you that unauthorized third parties have gained such access or that any data has been otherwise compromised during transmission across computer networks or telecommunications facilities, including, but not limited to, the Internet. We will not be responsible or liable for any damages, losses or causes of action arising out of or in connection with the disclosure of your personally identifiable information.